Correlation between clinical-disease characteristics and compliance with immunotherapy in solid metastatic tumors patients in a real-world setting: Italian CORE-IMMUNO study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 May 2019

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms CORE-IMMUNO

31 May 2019 Results assessing safety and clinical-related biomarkers as predictors of immunotherapy (n=169) published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
10 Jan 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com